Nintedanib
Sign in to save this workspacePrimary targets: FGFR1, FGFR2, FGFR3 · FDA status: FDA Approved
Selectivity scorecard
KISS
90.23
Gini
0.608
CATDS
0.008
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Nintedanib. Strongest target: DDR2 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | DDR2 | 100.0% | 0.0% |
| 2 | LCK | 100.0% | 0.0% |
| 3 | RET | 100.0% | 0.0% |
| 4 | ABL1 | 99.9% | 0.1% |
| 5 | MELK | 99.4% | 0.6% |
| 6 | SIK2 | 99.4% | 0.6% |
| 7 | FLT4_VEGFR3 | 99.2% | 0.8% |
| 8 | MEK5 | 98.6% | 1.4% |
| 9 | PDGFRA | 98.3% | 1.7% |
| 10 | BTK | 98.0% | 2.0% |
| 11 | LYN | 97.9% | 2.1% |
| 12 | YES_YES1 | 97.9% | 2.1% |
| 13 | BLK | 97.6% | 2.4% |
| 14 | FGFR2 | 97.0% | 3.0% |
| 15 | C_SRC | 96.9% | 3.1% |
| 16 | C_KIT | 96.8% | 3.2% |
| 17 | TRKC | 96.7% | 3.3% |
| 18 | KDR_VEGFR2 | 96.4% | 3.6% |
| 19 | DDR1 | 96.1% | 3.9% |
| 20 | PDGFRB | 96.0% | 4.0% |
Selectivity landscape
Where Nintedanib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Nintedanib.
Annotations
Sign in to read and post annotations.
Loading…